Timothy J. Kaufmann, M.D., M.S.

Closed for Enrollment

• EAF151, Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

  This phase II trial studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blood vessels within the cancer to determine a patient?s response to treatment.

• Idiopathic Cord Displacement Myelopathy: Clinical and Radiologic Characteristics and Outcomes, Short and Long Term, of Intervention Rochester, Minn.

  The purpose of this study is to investigate the clinical presentation, radiological findings, surgical treatment, and the subsequent clinical course and outcomes of cases of myelopathy associated with idiopathic/cryptogenic causes of spinal cord displacement who have been evaluated at Mayo Clinic.